What Next for Intra-Cellular Therapies, Inc. (ITCI) Stock After Making 52-Week High?

March 15, 2018 - By Louis Casey

Investors sentiment increased to 2.77 in Q3 2017. Its up 1.91, from 0.86 in 2017Q2. It increased, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported.
Moreover, Tower Cap Limited Liability Company (Trc) has 0.01% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). New York-based Baker Bros L P has invested 0.08% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Dubuque Bancshares And Tru invested 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Clough Prtn L P invested in 0.7% or 658,750 shares. Rock Springs Capital Mgmt Ltd Partnership invested in 187,500 shares or 0.14% of the stock. Stifel invested in 0% or 14,850 shares. Geode Capital Management Ltd Limited Liability Company reported 337,189 shares stake. Citigroup Inc has 12,188 shares for 0% of their portfolio. Moreover, Vanguard Grp has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). 18,010 were accumulated by C M Bidwell Assocs Limited. Ameritas Inv Prns Inc has 2,964 shares. Credit Suisse Ag stated it has 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). American Intll Group reported 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). 5,330 are owned by Acadian Asset Mngmt Limited Liability Corp. Pub Employees Retirement Sys Of Ohio holds 69,191 shares or 0.01% of its portfolio.

Since September 29, 2017, it had 3 insider purchases, and 10 selling transactions for $9.93 million activity. $82,725 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was sold by Hineline Lawrence J. on Wednesday, January 3. The insider Davis Robert E sold 1,115 shares worth $17,394. 258,065 shares valued at $4.00M were bought by ALAFI CAPITAL CO LLC on Monday, October 2. ALAFI MOSHE bought 258,065 shares worth $4.00 million. Another trade for 772 shares valued at $13,479 was sold by Vanover Kimberly E.. Another trade for 6,604 shares valued at $115,438 was sold by Mates Sharon.

The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) hit a new 52-week high and has $27.73 target or 9.00 % above today’s $25.44 share price. The 7 months bullish chart indicates low risk for the $1.39 billion company. The 1-year high was reported on Mar, 15 by Barchart.com. If the $27.73 price target is reached, the company will be worth $125.19 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.20% or $0.05 during the last trading session, reaching $25.44. About 165,044 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since March 15, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on May, 9. They expect $-0.65 earnings per share, down 4.84 % or $0.03 from last year’s $-0.62 per share. After $-0.56 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts 16.07 % negative EPS growth.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 13 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Intra-Cellular Therapies had 44 analyst reports since August 6, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Buy” rating and $28.0 target in Thursday, March 1 report. As per Wednesday, August 30, the company rating was upgraded by Ladenburg. RBC Capital Markets maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Friday, November 6 with “Outperform” rating. Cowen & Co maintained the stock with “Buy” rating in Tuesday, June 6 report. As per Thursday, September 7, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, August 23 with “Buy” rating. SunTrust upgraded Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, November 8 to “Buy” rating. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Buy” rating by J.P. Morgan on Monday, February 26. The company was upgraded on Friday, August 7 by Zacks. On Thursday, September 7 the stock rating was upgraded by Piper Jaffray to “Buy”.

More recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Globenewswire.com which released: “Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial …” on March 01, 2018. Also Globenewswire.com published the news titled: “Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial …” on February 22, 2018. Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: February 26, 2018 was also an interesting one.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $1.39 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.